Key facts
- This page summarizes Michael O'Grady's Form 4 filing for ABBOTT LABORATORIES (ABT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 30 Apr 2024, 18:11.
Michael O'Grady - 26 Apr 2024 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)
- Reporting relationship
- Director
- Issuer ticker
- ABT
- Reported as of
- 26 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Apr 2024, 18:11:01 UTC
- Prior SEC filing
- 05 Mar 2024
- Next SEC filing
- 05 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael G. O'Grady by Jessica H. Paik, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael O'Grady filed Form 4 for ABBOTT LABORATORIES (ABT) on 30 Apr 2024.
Change
- Previous filing in this sequence was filed on 05 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABT
transaction
Common shares without par value
Award
- Transaction value
- $0
- Shares
- +1,866
- Change %
- +103%
- Price
- $0.000000
- Shares after
- 3,682
- Date
- 26 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABT
transaction
Derivative
Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +4,404
- Change %
- Price
- $0.000000
- Shares after
- 4,404
- Date
- 26 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 4,404
- Exercise price
- $107.14
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Footnote F2
Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.